Showing 4031-4040 of 5983 results for "".
- ASLMS News: BTL Unveils EXIONhttps://practicaldermatology.com/news/aslms-news-btl-unveils-exion/2461661/Just in time for their 30th anniversary, BTL is launching EXION, a multiplatform device featuring micro-needling RF, a non-invasive face and body applicator for skin laxity, and the EMFEMME 360 applicator for intimate health. EXION can also be combined with EMFACE to treat bot
- Cutera CEO, Executive Chairman Axedhttps://practicaldermatology.com/news/shake-up-at-cutera-shareholder-ceo-look-to-reconstitute-board/2461654/Cutera, Inc. has fired CEO David Mowry and Executive Chairman Daniel Plants for alleged violations of their employment contracts. Sheila Hopkins has been appointed as interim CEO and the search for a permanent replacement is underway. Plants and Mowry called for a Sp
- Dr. Susan C. Taylor Elected 2025 AAD Presidenthttps://practicaldermatology.com/news/dr-susan-c-taylor-elected-2025-aad-president/2461653/Susan C. Taylor, MD, FAAD is the American Academy of Dermatology’s president-elect. She will be installed in March 2024 and hold the office of president for one year beginning in March 2025. Dr. Taylor previously served as AAD Vice President from 2020 – 2021.
- Dr. James G. Krueger Joins ASA’s Board of Directorshttps://practicaldermatology.com/news/dr-james-g-krueger-joins-asas-board-of-directors/2461651/James G. Krueger, MD, PhD, will join the American Skin Association’s (ASA) Board of Directors. Dr. Krueger is the David Martin Carter Professor in Clinical Investigation and Head of the Laboratory for Investigative Dermatology at The Rockefeller University in&
- First Patient Dosed in Phase 2 Trial of ADX-629 in ADhttps://practicaldermatology.com/news/first-patient-dosed-in-phase-2-trial-of-adx-629-in-ad/2461650/Aldeyra Therapeutics, Inc.
- The American Acne and Rosacea Society Offers #RosaceaRescues During Rosacea Awareness Monthhttps://practicaldermatology.com/news/the-american-acne-and-rosacea-society-offers-rosacearescues-during-rosacea-awareness-month/2461647/In recognition of National Rosacea Awareness Month in April, experts from the American Acne and Rosacea Society (AARS) are working to educate the public about the disease, its impact, and its treatment. Throughout the month, they are sharing #RosaceaRescues—science-backed, medically-based s
- Building a Better Sunscreen: Is Rosmarinic Acid the Key?https://practicaldermatology.com/news/building-a-better-sunscreen-is-rosmarinic-acid-the-key/2461646/Rosmarinic acid may enhance sunscreen efficacy without increasing concentration of conventional UV filters, a new study in Cosmetics suggests. When 0.1% Rosmarinic acid an active antioxidant was added
- Mount Sinai Wins $1.3M Grant to Expand Skin Biology Research Training Programhttps://practicaldermatology.com/news/mount-sinai-wins-13m-grant-to-expand-skin-biology-research-training-program/2461643/The Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai will expand its research training program in skin biology with support from a five-year, $1.3 million T32 grant from the National Institutes of Health (NIH) and the National Institute of Arth
- Phase 3 Data Evaluating Almirall’s Lebrikizumab in Moderate-to-Severe Atopic Dermatitis Publishedhttps://practicaldermatology.com/news/phase-3-data-evaluating-almiralls-lebrikizumab-in-moderate-to-severe-atopic-dermatitis-published/2461640/Almirall announced the publication of Week 16 and Week 52 results of ADvocate1 and ADvocate2 by the New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD), respectively. ADvocate1 and ADvocate2 are two identical 52-week randomized, double-blind, plac
- FDA Approves Humira Biosimilar Hyrimozhttps://practicaldermatology.com/news/fda-approves-humira-biosimilar-hyrimoz/2461636/The FDA approved a citrate-free high-concentration formulation (HCF) of Hyrimoz (adalimumab-adaz; Sandoz) injection, a biosimilar to Humira (adalimumab). The adalimumab citrate-free HCF (100 mg/mL) is approved to treat seven indications covered by the reference medicine, Humira, in